Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of ADC Therapeutics's ADCT-602?
ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic...
Risk adjusted net present value: What is the current valuation of ADC Therapeutics's ADCT-602?
ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic...
ADCT-602 by ADC Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
ADCT-602 is under clinical development by ADC Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...